Intracranial responses with selective KRAS-G12C inhibitors in non-small cell lung cancer

被引：1
|
作者：
Lu, Kevin [1 ]
Husain, Hatim [1 ,2 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA USA
[2] Univ Calif San Diego, Div Med Oncol, 3855 Hlth Sci 3011, La Jolla, CA 92093 USA
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2023年 / 12卷 / 06期
关键词：
Non-small cell lung cancer (NSCLC); KRAS G12C; adagrasib; sotorasib; BRAIN METASTASES; NSCLC;
D O I：
10.21037/tlcr-23-26
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1335 / 1337
页数：3
相关论文
共 50 条
  • [31] KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies
    Naim, Nabih
    Moukheiber, Sara
    Daou, Samah
    Kourie, Hampig Raphael
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 168
  • [32] Activity and resistance to KRASG12C G12C inhibitors in non-small cell lung cancer and colorectal cancer
    Ye, Wei
    Lu, Xin
    Qiao, Yue
    Ou, Wen-Bin
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2024, 1879 (03):
  • [33] The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): Differences between KRAS G12C and non-G12C
    Notario Rincon, L.
    Pous, A.
    Lopez-Paradis, A.
    Cerda, G.
    Cucurull, M.
    Hernandez, A.
    Domenech, M.
    Carcereny, E.
    Moran Bueno, M. T.
    Munoz, A.
    Mate, J. L.
    Sanz, C.
    Saigi, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S50 - S50
  • [34] Efficacy of JS']JSI-1187 or VIC-1911 in combination with KRAS G12C inhibitors for the treatment of KRAS G12C-mutated non-small cell lung cancer and colorectal cancer
    Zhang, Lei
    Li, Ao
    Jian, Shanzhong
    Du, Chengyi
    Zhu, Wan
    Tao, Yue
    Wang, Meiwei
    Xu, Wen
    Hao, Wenshan
    Paradiso, Linda
    Myers, Thomas
    Koya, Keizo
    Zhang, Jintao
    CANCER RESEARCH, 2023, 83 (07)
  • [35] Repotrectinib increases effectiveness of KRAS-G12C inhibitors in KRAS-G12C mutant cancer models via simultaneous SRC/FAK/JAK2 inhibition
    Cui, J. Jean
    Zhai, Dayong
    Deng, Wei
    Rodon, Laura
    Lee, Nathan
    Murray, Brion
    CANCER RESEARCH, 2020, 80 (16)
  • [36] Combination Therapies to Maximize the Impact of KRAS-G12C Inhibitors
    Molina-Arcas, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S97 - S97
  • [37] GTPase KRAS (G12C mutant) inhibitor Treatment of non-small cell lung cancer Treatment of colorectal cancer
    Shao, Shi-yun
    Rong, Wen-qing
    Talukder, Salehikram
    Jia, Ru
    Chen, Zhe-Sheng
    DRUGS OF THE FUTURE, 2022, 47 (11) : 783 - 795
  • [38] KRAS codon 12 mutations in Australian non-small cell lung cancer
    Fong, KM
    Zimmerman, PV
    Smith, PJ
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1998, 28 (02): : 184 - 189
  • [39] Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Cardona, Andres Felipe
    Recondo, Gonzalo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [40] Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
    Shahnam, Adel
    Davis, Alexander
    Brown, Lauren Julia
    Sullivan, Isaac
    Lin, Kevin
    Ng, Chien
    Yeo, Nicholas
    Kong, Benjamin Y.
    Khoo, Trisha
    Warburton, Lydia
    Da Silva, Ines Pires
    Mullally, William
    Xu, Wen
    O'Byrne, Ken
    Bray, Victoria
    Pal, Abhijit
    Mersaides, Antony
    Itchins, Malinda
    Arulananda, Surein
    Nagrial, Adnan
    Kao, Steven
    Alexander, Marliese
    Lee, Chee Khoon
    Solomon, Benjamin
    John, Thomas
    LUNG CANCER, 2025, 201
12345